- Home
- Products
- Customized ADCs
- TNFRSF8
- Anti-TNFRSF8-DIBO-doxorubicin ADC-12
Anti-TNFRSF8-DIBO-doxorubicin ADC-12 (CAT#: ADC-W-340)
This ADC product is comprised of an anti-TNFRSF8 monoclonal antibody (cAC10) conjugated via a DIBO linker to a doxorubicin. The doxorubicin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, doxorubicin binds to DNA, causes DNA damage.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- TNFRSF8
- Alternative Names
- TNFRSF8; tumor necrosis factor receptor superfamily, member 8; CD30; Ki-1; D1S166E; tumor necrosis factor receptor superfamily member 8; Ki-1 antigen; CD30L receptor; cytokine receptor CD30; lymphocyte activation antigen CD30;
- Target Entrez Gene ID
- 943
- Target UniProt ID
- A5D8T4
- Overview
- The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. This receptor is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.
- Overview
- Chimeric Anti-TNFRSF8 Antibody, cAC10
- Generic name
- cAC10
- Species Reactivity
- Human
- Name
- DIBO (dibenzylcyclooctynol)
- Name
- doxorubicin
- Description
- Doxorubicin is a type of anti-cancer chemotherapy drug called an anthracycline. Doxorubicin works by blocking an enzyme called TopoisomeraseⅡthat cancer cells need to divide and grow.
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-340. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-2344 | Anti-TNFRSF8 (Brentuximab )-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-1887 | Anti-TNFRSF8 (Iratumumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-2346 | Anti-TNFRSF8 (Brentuximab )-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-1888 | Anti-TNFRSF8 (Iratumumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2345 | Anti-TNFRSF8 (Brentuximab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| CAT# | Product Name | Linker | Payload |
| ADC-W-339 | Anti-CD22-DIBO-doxorubicin ADC | DIBO (dibenzylcyclooctynol) | doxorubicin |
| CAT# | Product Name | Linker | Payload |
| ADC-W-600 | Anti-EGFR-doxorubicin ADC | polyethylene glycol linker | doxorubicin |
| ADC-W-502 | Anti-EGFR-SMCC-Dox ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | Doxorubicin |
| ADC-W-503 | Anti-EGFR-EDC/NHS-Dox ADC | EDC/NHS(1-ethyl-3-(3-diaminopropyl)carbodiimide/N-hydroxysuccinimide) | Doxorubicin |
| ADC-W-602 | Anti-FOLR1-S-S-Dox ADC | disulfide (“S-S”) linker | doxorubicin |
| ADC-W-571 | Anti-ERBB2 (Trastuzumab)-DOX ADC | thiomaleamicacids-p-aminobenzyloxycarbonyl | doxorubicin |
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-TNFRSF13B (Tabalumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1909)
- Anti-FAP (Sibrotuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1135)
- Anti-ITGB2 (Rovelizumab)-SPDB-DM4 ADC (CAT#: ADC-W-1503)
- Anti-FUT4 (Technetium (99mTc) fanolesomab)-SMCC-DM1 ADC (CAT#: ADC-W-1172)
- Anti-CCR5 (PRO 140)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-769)
- Anti-CFD (Lampalizumab)-SPDB-DM4 ADC (CAT#: ADC-W-981)
- Anti-CFD (Lampalizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-985)
- Anti-NCAM1 (Lorvotuzumab )-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-2342)
- Anti-FOLH1-Mc-MMAF ADC (CAT#: ADC-W-158)
- Anti-EGFR (Nimotuzumab)-MC-MMAF ADC (CAT#: ADC-W-1060)
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
